Success Metrics

Clinical Success Rate
57.1%

Based on 8 completed trials

Completion Rate
57%(8/14)
Active Trials
0(0%)
Results Posted
125%(10 trials)
Terminated
6(33%)

Phase Distribution

Ph phase_2
2
11%
Ph not_applicable
2
11%
Ph early_phase_1
1
6%
Ph phase_4
10
56%
Ph phase_3
1
6%

Phase Distribution

1

Early Stage

2

Mid Stage

11

Late Stage

Phase Distribution16 total trials
Early Phase 1First-in-human
1(6.3%)
Phase 2Efficacy & side effects
2(12.5%)
Phase 3Large-scale testing
1(6.3%)
Phase 4Post-market surveillance
10(62.5%)
N/ANon-phased studies
2(12.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

8 of 16 finished

Non-Completion Rate

50.0%

8 ended early

Currently Active

0

trials recruiting

Total Trials

18

all time

Status Distribution
Completed(8)
Terminated(8)
Other(2)

Detailed Status

Completed8
Terminated6
unknown2
Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials
18
Active
0
Success Rate
57.1%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (6.3%)
Phase 22 (12.5%)
Phase 31 (6.3%)
Phase 410 (62.5%)
N/A2 (12.5%)

Trials by Status

completed844%
terminated633%
unknown211%
withdrawn211%

Recent Activity

0 active trials
Showing 5 of 18
completedphase_3

Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation

NCT02683889
completedphase_4

Use of Acthar in Rheumatoid Arthritis (RA) Related Flares

NCT02541955
terminatedphase_4

Effects of ACTHAR on Advanced MRI Surrogate Markers of Disease Activity and on Comprehensive Immune Signature During MS Relapses

NCT03021317
completedphase_4

Adrenocorticotropic Hormone in Membranous Nephropathy

NCT03025828
completedphase_4

Clinical Impact of Acthar in the Psoriatic Arthritis Patient (CLIPS)

NCT03419650
View all 18 trials

Clinical Trials (18)

Showing 18 of 18 trials
NCT02683889Phase 3

Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation

Completed
NCT02541955Phase 4

Use of Acthar in Rheumatoid Arthritis (RA) Related Flares

Completed
NCT03021317Phase 4

Effects of ACTHAR on Advanced MRI Surrogate Markers of Disease Activity and on Comprehensive Immune Signature During MS Relapses

Terminated
NCT03025828Phase 4

Adrenocorticotropic Hormone in Membranous Nephropathy

Completed
NCT03419650Phase 4

Clinical Impact of Acthar in the Psoriatic Arthritis Patient (CLIPS)

Completed
NCT02399462Phase 4

Acthar for Treatment of Post-transplant FSGS

Withdrawn
NCT04169061Phase 4

Impact of Acthar on Everyday Life of Participants With Severe Keratitis

Completed
NCT01984268Phase 2

ACTHAR for Acute Treatment of Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate

Terminated
NCT03068754Phase 2

Study of Acthar® Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS)

Terminated
NCT02057523Phase 4

Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients

Terminated
NCT02258217Not Applicable

Tolerability of Acthar for the Treatment of Multiple Sclerosis in Relapses (TAMS)

Completed
NCT01753401Phase 4

Acthar for the Treatment of Systemic Lupus Erythematosus (SLE) in Patients With a History of Persistently Active Disease

Completed
NCT03644771

Experience With H.P. Acthar Gel Treatment of Patients With Nephrotic Syndrome/Proteinuria Due to Various Etiologies and Its Effect on Podocyte Function

Unknown
NCT02769702Phase 4

Open Label Study of Acthar SQ Gel Injection in Patients With Active Anterior Uveitis

Terminated
NCT02006849Not Applicable

ACTH Treatment of APOL1- Associated Nephropathy

Withdrawn
NCT01987167Early Phase 1

Defining the Functional and Neuro-Protective Potential of ACTHAR in Acute Optic Neuritis

Completed
NCT01637064

Dermatomyositis and Polymyositis Registry

Unknown
NCT00854750Phase 4

Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis

Terminated

All 18 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
18